Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - nicorandil, quantity: 20 mg - tablet, uncoated - excipient ingredients: maize starch; stearic acid; mannitol; croscarmellose sodium - ikorel is indicated for the treatment of chronic stable angina pectoris.

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - nicorandil, quantity: 10 mg - tablet, uncoated - excipient ingredients: mannitol; maize starch; croscarmellose sodium; stearic acid - ikorel is indicated for the treatment of chronic stable angina pectoris.

Malaisia - inglise - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

cap seen shei herbs enterprise - methyl salicylate; menthol -

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - perhexiline maleate, quantity: 100 mg - tablet, uncoated - excipient ingredients: maize starch; purified talc; sucrose; lactose monohydrate - to reduce the frequency of moderate to severe attacks of angina pectoris due to coronary artery disease in patients who have not responded to other conventional therapy or in whom such therapy may be contra-indicated. note: because of the serious nature of potential side effects, perhexiline maleate should be reserved for use in patients with intractable angina who are refactory or intolerant to other agents and who are not suitable canditates for coronary bypass surgery.

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - diltiazem hydrochloride, quantity: 60 mg - tablet, film coated - excipient ingredients: lactose monohydrate; hydrogenated castor oil; aluminium hydroxide; methacrylic acid copolymer; purified talc; magnesium stearate; titanium dioxide; indigo carmine; methylcellulose; macrogol 400 - moderate to severe angina pectoris due to atherosclerotic coronary artery disease or coronary artery spasm (vasospastic angina).

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - atenolol, quantity: 5 mg/ml - oral liquid, solution - excipient ingredients: propylene glycol; propyl hydroxybenzoate; saccharin sodium; purified water; citric acid monohydrate; sorbitol solution (70 per cent) (non-crystallising); sodium citrate dihydrate; methyl hydroxybenzoate; flavour - all grades of hypertension including hypertension of renal origin.,frequent disabling angina without evidence of cardiac failure,cardiac arrhythmias (acute treatment of supraventricular and ventricular arrhythmias including those with acute myocardial infarction),myocardial infarction - late intervention (beta-blocker class effect greater than 12 hours after onset of chest pain)

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - amlodipine besilate, quantity: 13.87 mg (equivalent: amlodipine, qty 10 mg); atorvastatin calcium trihydrate, quantity: 86.8 mg (equivalent: atorvastatin, qty 80 mg) - tablet, film coated - excipient ingredients: calcium carbonate; pregelatinised maize starch; croscarmellose sodium; polysorbate 80; hyprolose; colloidal anhydrous silica; microcrystalline cellulose; magnesium stearate; titanium dioxide; indigo carmine; purified talc; polyvinyl alcohol; macrogol 3000 - caduet (amlodipine and atorvastatin) is indicated for patients in whom treatment with amlodipine and atorvastatin is appropriate at the doses presented. the indications for amlodipine are: 1. hypertension: amlodipine is indicated for the first line treatment of hypertension and can be used as the sole agent to control blood pressure in the majority of patients. patients not adequately controlled on a single antihypertensive agent may benefit from the addition of amlodipine, which has been used in combination with a thiazide diuretic, beta adrenoceptor blocking agent or an angiotensin-converting enzyme inhibitor. 2. angina: amlodipine is indicated for the first line treatment of chronic stable angina. amlodipine may be used alone, as monotherapy or in combination with other antianginal drugs. the indications for atorvastatin are: 1. atorvastatin is indicated as an adjunct to diet for the treatment of patients with hypercholesterolaemia. prior to initiating therapy with atorvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, and alcoholism) should be identified and treated. 2. atorvastatin is indicated in hypertensive patients with multiple risk factors for coronary heart disease (chd) which may include diabetes, history of stroke or other cerebrovascular disease, peripheral vascular disease or existing asymptomatic chd (see clinical trials, prevention of cardiovascular disease) to reduce the risk of non-fatal myocardial infarction and non-fatal stroke. these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking.

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - atorvastatin calcium trihydrate, quantity: 43.4 mg (equivalent: atorvastatin, qty 40 mg); amlodipine besilate, quantity: 13.87 mg (equivalent: amlodipine, qty 10 mg) - tablet, film coated - excipient ingredients: colloidal anhydrous silica; calcium carbonate; microcrystalline cellulose; croscarmellose sodium; hyprolose; magnesium stearate; pregelatinised maize starch; polysorbate 80; titanium dioxide; indigo carmine; purified talc; polyvinyl alcohol; macrogol 3000 - caduet (amlodipine and atorvastatin) is indicated for patients in whom treatment with amlodipine and atorvastatin is appropriate at the doses presented. the indications for amlodipine are: 1. hypertension: amlodipine is indicated for the first line treatment of hypertension and can be used as the sole agent to control blood pressure in the majority of patients. patients not adequately controlled on a single antihypertensive agent may benefit from the addition of amlodipine, which has been used in combination with a thiazide diuretic, beta adrenoceptor blocking agent or an angiotensin-converting enzyme inhibitor. 2. angina: amlodipine is indicated for the first line treatment of chronic stable angina. amlodipine may be used alone, as monotherapy or in combination with other antianginal drugs. the indications for atorvastatin are: 1. atorvastatin is indicated as an adjunct to diet for the treatment of patients with hypercholesterolaemia. prior to initiating therapy with atorvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, and alcoholism) should be identified and treated. 2. atorvastatin is indicated in hypertensive patients with multiple risk factors for coronary heart disease (chd) which may include diabetes, history of stroke or other cerebrovascular disease, peripheral vascular disease or existing asymptomatic chd (see clinical trials, prevention of cardiovascular disease) to reduce the risk of non-fatal myocardial infarction and non-fatal stroke. these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking.

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - atorvastatin calcium trihydrate, quantity: 21.7 mg (equivalent: atorvastatin, qty 20 mg); amlodipine besilate, quantity: 13.87 mg (equivalent: amlodipine, qty 10 mg) - tablet, film coated - excipient ingredients: polysorbate 80; pregelatinised maize starch; colloidal anhydrous silica; microcrystalline cellulose; croscarmellose sodium; calcium carbonate; magnesium stearate; hyprolose; titanium dioxide; indigo carmine; purified talc; polyvinyl alcohol; macrogol 3000 - caduet (amlodipine and atorvastatin) is indicated for patients in whom treatment with amlodipine and atorvastatin is appropriate at the doses presented. the indications for amlodipine are: 1. hypertension: amlodipine is indicated for the first line treatment of hypertension and can be used as the sole agent to control blood pressure in the majority of patients. patients not adequately controlled on a single antihypertensive agent may benefit from the addition of amlodipine, which has been used in combination with a thiazide diuretic, beta adrenoceptor blocking agent or an angiotensin-converting enzyme inhibitor. 2. angina: amlodipine is indicated for the first line treatment of chronic stable angina. amlodipine may be used alone, as monotherapy or in combination with other antianginal drugs. the indications for atorvastatin are: 1. atorvastatin is indicated as an adjunct to diet for the treatment of patients with hypercholesterolaemia. prior to initiating therapy with atorvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, and alcoholism) should be identified and treated. 2. atorvastatin is indicated in hypertensive patients with multiple risk factors for coronary heart disease (chd) which may include diabetes, history of stroke or other cerebrovascular disease, peripheral vascular disease or existing asymptomatic chd (see clinical trials, prevention of cardiovascular disease) to reduce the risk of non-fatal myocardial infarction and non-fatal stroke. these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking.

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - amlodipine besilate, quantity: 13.87 mg (equivalent: amlodipine, qty 10 mg); atorvastatin calcium trihydrate, quantity: 10.85 mg (equivalent: atorvastatin, qty 10 mg) - tablet, film coated - excipient ingredients: calcium carbonate; pregelatinised maize starch; hyprolose; polysorbate 80; microcrystalline cellulose; magnesium stearate; colloidal anhydrous silica; croscarmellose sodium; titanium dioxide; indigo carmine; purified talc; polyvinyl alcohol; macrogol 3000 - caduet (amlodipine and atorvastatin) is indicated for patients in whom treatment with amlodipine and atorvastatin is appropriate at the doses presented. the indications for amlodipine are: 1. hypertension: amlodipine is indicated for the first line treatment of hypertension and can be used as the sole agent to control blood pressure in the majority of patients. patients not adequately controlled on a single antihypertensive agent may benefit from the addition of amlodipine, which has been used in combination with a thiazide diuretic, beta adrenoceptor blocking agent or an angiotensin-converting enzyme inhibitor. 2. angina: amlodipine is indicated for the first line treatment of chronic stable angina. amlodipine may be used alone, as monotherapy or in combination with other antianginal drugs. the indications for atorvastatin are: 1. atorvastatin is indicated as an adjunct to diet for the treatment of patients with hypercholesterolaemia. prior to initiating therapy with atorvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, and alcoholism) should be identified and treated. 2. atorvastatin is indicated in hypertensive patients with multiple risk factors for coronary heart disease (chd) which may include diabetes, history of stroke or other cerebrovascular disease, peripheral vascular disease or existing asymptomatic chd (see clinical trials, prevention of cardiovascular disease) to reduce the risk of non-fatal myocardial infarction and non-fatal stroke. these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking.